CJC-1295 vs Ipamorelin: evidence, safety and FDA status

PepsRadar · Comparison · AI-assisted, written from the checked facts on each profile · Content updated October 11, 2026 (how dates work) · Not reviewed by a medical professional

The short answer

Both are unapproved compounds that raise growth hormone, by different routes. CJC-1295 mimics growth-hormone-releasing hormone (GHRH); ipamorelin acts on the ghrelin receptor as a growth-hormone secretagogue. Their human data are small and short, and none of it shows a health benefit.

Key differences

CJC-1295’s human trials measured hormone levels: growth hormone rose two- to tenfold and IGF-1 1.5- to threefold after a single exposure. They did not measure muscle, fat or recovery.
Those trials studied the long-acting (DAC) form. Most sellers offer a “no DAC” version, which is a different preparation.
Ipamorelin’s one randomized trial, in 117 people after bowel surgery, did not show a significant benefit on its main measure.
FDA cites serious events for both: a faster heart rate and a body-wide vasodilation reaction for CJC-1295, and serious events including a death in a study of intravenous ipamorelin.

Side by side

Fact	CJC-1295	Ipamorelin
FDA status	Not FDA-approved	Not FDA-approved
What it is	CJC-1295 is a growth-hormone-releasing-hormone analogue. The foundational human trials studied a long-acting preparation and measured endocrine responses.	Ipamorelin was developed as a growth-hormone secretagogue. Its often-cited selectivity comes from early pharmacology experiments, not a comprehensive human safety program.
Human evidence	No randomized trials · pharmacology trials · physiology study	1 randomized trial
Human safety data	Very limited. CJC-1295 is an unapproved growth-hormone-releasing analogue. Small, short trials reported no serious reactions, but FDA cites serious events including a faster heart rate and a body-wide vasodilation reaction.	Trials only. Ipamorelin is an unapproved growth-hormone secretagogue. One surgical trial found adverse events similar to placebo, but FDA notes a published report of serious events, including death, with intravenous use.
Boxed warning	No FDA label to carry one	No FDA label to carry one
Serious risks	FDA: increased heart rate and systemic vasodilatory reaction reported FDA: possible immune reactions (immunogenicity) and peptide-impurity problems with compounded products	FDA: serious adverse events including death reported in a study of intravenous ipamorelin for gut motility FDA: possible immune reactions (immunogenicity); unnatural amino acids complicate quality testing
Conditions flagged	Heart or blood pressure problems	None flagged
Claim check	Partly supported: Peptides like CJC-1295/ipamorelin are a safe, natural way to boost growth hormone.	Partly supported: Peptides like CJC-1295/ipamorelin are a safe, natural way to boost growth hormone.

Each row comes from the CJC-1295 and Ipamorelin profiles, where every fact links to its source. “Conditions flagged” lists the health conditions each profile’s Risks & interactions section mentions.

The human studies

CJC-1295

Long-acting CJC-1295 (2006)

Human pharmacology trials · Healthy adults aged 21–61.

Mean growth hormone rose two- to tenfold for at least six days; IGF-1 rose 1.5- to threefold for nine to eleven days after a single exposure. The estimated half-life was 5.8–8.1 days.

Limitation: The endpoints were hormone concentrations. These were studies of long-acting CJC-1295, not proof of muscle gain or equivalence to products labeled “CJC no DAC.”

Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. ↗

Growth-hormone pulsatility after long-acting CJC-1295 (2006)

Human physiology study · Healthy men aged 20–40 years.

GH pulses persisted. Trough GH increased markedly, while mean GH and IGF-I also increased. Pulse frequency and magnitude were not significantly altered in the reported assessment.

Limitation: Short physiological follow-up in healthy men. These results concern the long-acting albumin-binding compound and should not be assigned automatically to products called “CJC without DAC.”

Ionescu and Frohman · JCEM · 2006 ↗

Ipamorelin

Postoperative ileus proof-of-concept trial (2014)

Human randomized trial · 117 patients enrolled after bowel resection; 114 in the safety and modified intention-to-treat populations.

Median time to tolerating a standardized meal was 25.3 hours with ipamorelin and 32.6 hours with placebo (p=0.15). Key and secondary efficacy analyses did not show significant between-group differences.

Limitation: Small proof-of-concept study with varied underlying conditions. This setting, route, and endpoint do not test muscle gain, fat loss, sleep improvement, or long-term use.

Beck et al. · International Journal of Colorectal Disease · 2014 ↗

Results from different trials are not a head-to-head comparison: the people, preparations, durations and measures differ.

Bottom line

Raising a hormone level is not the same as building muscle or speeding recovery, and no trial of either compound shows those outcomes. Sold together as a blend, they combine two compounds with thin safety records.

PepsRadar does not give doses or usage instructions, and this page is not medical advice. For a prescription medicine, talk to your prescriber or pharmacist.

Other comparisons: BPC-157 vs TB-500 · Semaglutide vs Tirzepatide · Tirzepatide vs Retatrutide · Sermorelin vs Tesamorelin · Selank vs Semax · MOTS-c vs Elamipretide · Ipamorelin vs MK-677 · AOD-9604 vs HGH Fragment 176-191 · Thymosin alpha-1 vs Thymosin beta-4 · Tesamorelin vs CJC-1295 · GHK-Cu vs AHK-Cu · Epitalon vs Pinealon

See something wrong on this page? Report a mistake · Corrections